We have located links that may give you full text access.
Clinical Trial
Journal Article
Treatment of Peyronie's disease with local interferon-alpha 2b.
BJU International 2001 May
OBJECTIVE: To evaluate the efficacy of subcutaneous interferon-alpha 2b in the treatment of Peyronie's disease.
PATIENTS AND METHODS: Twenty-three men (mean age 53 years, range 27-69) received interferon-alpha 2b in an unrandomized prospective study. The drug was injected subcutaneously adjacent to the plaque three times a week for 3 weeks at a dose of 2 x 106 IU. The effect of interferon-alpha 2b on the extent of penile deviation, plaque size and erectile pain were investigated, and the drug's side-effects were documented. The mean (range) follow-up was 22 (4-48) months
RESULTS: All patients had pain relief and 13 of 19 with pain before treatment became pain-free. The penile deviation was reduced in one patient; the deviation increased despite therapy in one patient and remained stable in the others. Plaque size remained unchanged in all patients. Impaired sexual function was improved in seven (30%) of the patients. Side-effects (myalgia, fever) occurred after only four of 207 injections (2%).
CONCLUSIONS: Subcutaneous interferon-alpha 2b is safe, well tolerated and relieves pain. However, with no objective reduction in penile deviation and plaque size, the outcome of interferon-alpha 2b therapy is generally unconvincing and the drug cannot be recommended for the conservative treatment of Peyronie's disease.
PATIENTS AND METHODS: Twenty-three men (mean age 53 years, range 27-69) received interferon-alpha 2b in an unrandomized prospective study. The drug was injected subcutaneously adjacent to the plaque three times a week for 3 weeks at a dose of 2 x 106 IU. The effect of interferon-alpha 2b on the extent of penile deviation, plaque size and erectile pain were investigated, and the drug's side-effects were documented. The mean (range) follow-up was 22 (4-48) months
RESULTS: All patients had pain relief and 13 of 19 with pain before treatment became pain-free. The penile deviation was reduced in one patient; the deviation increased despite therapy in one patient and remained stable in the others. Plaque size remained unchanged in all patients. Impaired sexual function was improved in seven (30%) of the patients. Side-effects (myalgia, fever) occurred after only four of 207 injections (2%).
CONCLUSIONS: Subcutaneous interferon-alpha 2b is safe, well tolerated and relieves pain. However, with no objective reduction in penile deviation and plaque size, the outcome of interferon-alpha 2b therapy is generally unconvincing and the drug cannot be recommended for the conservative treatment of Peyronie's disease.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app